Supplemental material
Journal of Dermatological Treatment
Volume 35, 2024 - Issue 1
RESEARCH ARTICLE
Cost per response analysis of deucravacitinib versus apremilast and first-line biologics among patients with moderate to severe plaque psoriasis in the United States
Sang Hee Parka Bristol Myers Squibb, Princeton, NJ, USA
https://orcid.org/0000-0003-2545-2938View further author information
https://orcid.org/0000-0003-2545-2938View further author information, , Jordana Schmierc OPEN Health Evidence and Access, Parsippany, NJ, USACorrespondence[email protected]
https://orcid.org/0000-0002-4662-8800View further author information
https://orcid.org/0000-0002-4662-8800View further author information, Sara Hovlanda Bristol Myers Squibb, Princeton, NJ, USAhttps://orcid.org/0009-0006-3102-2378View further author information
https://orcid.org/0009-0006-3102-2378View further author information, Keith Wittstocka Bristol Myers Squibb, Princeton, NJ, USAhttps://orcid.org/0000-0002-4080-1916View further author information
https://orcid.org/0000-0002-4080-1916View further author information & Vardhaman Patela Bristol Myers Squibb, Princeton, NJ, USAhttps://orcid.org/0000-0002-3636-3423View further author information
https://orcid.org/0000-0002-3636-3423View further author information